TC-I 15

TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, [1][2].

Product Specifications

CAS Number

[916734-43-5]

UNSPSC

12352005

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/tc-i-15.html

Purity

99.94

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=[S](N(CSC(C)1C)[C@@H]1C(N[C@H](C(O)=O)CNC(NCC2=CC=CC=C2)=O)=O)(C3=CC=CC=C3)=O

Molecular Formula

C23H28N4O6S2

Molecular Weight

520.62

References & Citations

[1]Emma J. Hunter, Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin. Toxicol Appl Pharmacol. 2021 Oct 1;428:115669.|[2]Jing Kong, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019 Dec 3;18 (1) :175.